Colon, Phase II-III
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Volunteers
Health Professionals
What is the purpose of this trial?
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Alison Johnson
- Anca Bulgaru, MD
- Armand Russo, MD
- Ashita Talsania, MRCP, MBBS
- Benjamin Newton, MD
- Beverly Drucker, MD, PhD
- David Witt, MD
- Elan Gorshein, DO, JD, MPH
- Jacquelyne Gaddy, MD, MSc, MSCR
- Jade Vanacore
- James Vredenburgh, MD
- Jane Kanowitz, MD
- Jill Lacy, MD
- Johanna LaSala, MD
- Justin Persico, MD
- Karen Ann Hammond, DNP, APRN, ACNP (BC)
- Katelyn Scott
- Kert Sabbath, MD, FACP
- Kristen Hoxie
- Larisa Fleysher
- Laura Sabourin
- Laura Van Metre Baum, MD, MPH
- M. Sung Lee, MD
- Michael Cecchini, MD
- Michael Cohenuram, MD
- Michael Grant, MD
- Neal Fischbach, MD
- Pamela L. Kunz, MD
- Pawan Karanam, MD
- Renee Moye
- Robert Legare, MD
- Sara Anastasio, RN
- Sarah Carlson
- Sarah Thomen, APRN
- Sharynn Hall, MD, PhD
- Stacey Stein, MD
- Stephen Lattanzi, MD
- Teresa White
- Vanna Dest
- Victor Chang, MD
- Vidya Kesavan
- Virginia Syombathy
- Wajih Kidwai, MD, FACP
- Yifei Zhang, MD
- Zia Rahman, MD
- Last Updated08/07/2024
- Study HIC#2000032928